Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH)

Dı́az, Emili; Menéndez, R. Amézaga; Vidal, Pablo; Escapa, M Gero; Suberviola, Borja; Lázaro, A. Serrano; Marcos-Neira, Pilar; Díaz, Manuel Quintana; González, Mercedes Catalán

doi:10.1016/j.medin.2020.06.017

Cited by 24 publications

(13 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 27 patients (100%) complied with ARDS criteria at the time of starting MV and received treatment with 0.5 mg/kg/12h of methylprednisolone. Treatment lasted 3 (3,4) days, with a median of 3 (2,4) in Group A patients and 3 (3, 4.2) in Group B patients (p=0.294).…”

Section: Resultsmentioning

confidence: 99%

“…COVID-19 has been a challenge for health systems all over the world; especially for ICUs that have had to expand to assume a number of patients that exceeded the number of beds available. At the same time, the lack of a known, effective treatment has led to a spate of treatment recommendations [1][2][3][4], which are not always backed by sufficient scientific evidence [5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome

Vidal-Cortés¹,

Río-Carbajo²,

Olmo³

et al. 2020

Rev Esp Quimioter

View full text Add to dashboard Cite

Objectives. To assess the impact of corticosteroids on inflammatory and respiratory parameters of patients with COVID-19 and acute respiratory distress syndrome (ARDS). Methods. Longitudinal, retrospective, observational study conducted in an ICU of a second level hospital. Adult patients with COVID-19 were included. Baseline characteristics, data on SARS-CoV-2 infection, treatment received, evolution of respiratory and inflammatory parameters, and ICU and hospital stay and mortality were analyzed. Results. A total of 27 patients were included, 63% men, median age: 68.4 (51.8, 72.2) years. All patients met ARDS criteria and received MV and corticosteroids. After corticosteroids treatment we observed a reduction in the O2 A-a gradient [day 0: 322 (249, 425); day 3: 169 (129.5, 239.5) p<0.001; day 5: 144 (127.5, 228.0) p<0.001; day 7: 192 (120, 261) p=0.002] and an increase in the pO2/FiO2 ratio on days 3 and 5, but not on day 7 [day 0: 129 (100, 168); day 3: 193 (140, 236) p=0.002; day 5: 183 (141, 255) p=0.004; day 7: 170 (116, 251) p=0.057]. CRP also decreased on days 3 and 5 and increased again on day 7 [day 0: 16 (8.6, 24); day 3: 3.4 (1.7, 10.2) p<0.001; day 5: 4.1 (1.4, 10.2) p<0.001; day 7: 13.5 (6.8, 17.3) p=0.063]. Persistence of moderate ARDS on day 7 was related to a greater risk of poor outcome (OR 6.417 [1.091-37.735], p=0.040). Conclusion. Corticosteroids appears to reduce the inflammation and temporarily improve the oxygenation in COVID-19 and ARDS patients. Persistence of ARDS after 7 days treatment is a predictor of poor outcome.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome

Vidal-Cortés¹,

Río-Carbajo²,

Olmo³

et al. 2020

Rev Esp Quimioter

View full text Add to dashboard Cite

show abstract

“…Sistema de información y estrategia de búsqueda de artículos sobre tratamiento farmacológico en pacientes con COVID- emtricitabina/tenofovir/alafenamida. (5,16,17,(25)(26)(27)(28)30,31,33,(35)(36)(37) Otros fármacos como antipalúdicos, antiparasitarios y antibacterianos con efecto antiviral en SARS-CoV-2 fueron CQ, HCQ sola o combinada con AZI e ivermectina (5,14,23,25,28,29,32,(34)(35)(36) nitazoxanida, teicoplanina, azitromicina y ceftriaxona (5,14,23) . Fármacos antiinflamatorios como corticoides, metilprednisolona, dexametasona y prednisona.…”

Section: Metodologíaunclassified

Tratamiento farmacológico en pacientes con COVID-19: una revisión integradora

Vargas¹,

Melendrez-Arango

Durán-Aguirre

et al. 2021

SANUS

View full text Add to dashboard Cite

Introducción: La salud hoy más que nunca ha sido vulnerada, la humanidad está sufriendo por la invasión del coronavirus SARS-CoV-2, que ha expuesto al mundo a la peor emergencia sanitaria en este siglo. La comunidad científica y los sistemas de salud global conjuntan esfuerzos en la búsqueda de un tratamiento definitivo, a la fecha se reconoce que la terapia está dirigida a mitigar los síntomas. Objetivo: Identificar las evidencias científicas sobre el tratamiento farmacológico en los pacientes con COVID-19. Metodología: Se realizó una revisión integradora de la literatura publicada de diciembre 2019 a octubre 2020, en los sistemas de información Clinical Key, Dialnet, EBSCO Host y Scopus, mediante los descriptores Coronavirus Infections, COVID-19, Drug therapy, tratamiento farmacológico. Los criterios de selección fueron artículos de investigación cuantitativa de cualquier tipo de diseño, en inglés y español disponibles a texto completo, obteniéndose una muestra de 24 artículos. Resultados: La mayoría de los estudios fueron revisiones integrativas con 66.6% y ensayos clínicos o in vitro con 12.5%. Se identificaron en la terapia farmacológica nueve medicamentos de mayor uso en COVID-19: Hidroxicloroquina/cloroquina, lopinavir/ritonavir, remdesivir, azitromicina, ivermectina, tocilizumab y dexametasona, no obstante, solo cuatro fármacos mostraron efectividad significativa según la evidencia científica. Conclusiones: remdesivir demostró mayor efectividad y seguridad en el tratamiento, tocilizumab y dexametasona mostraron resultados favorables, sin embargo, los resultados no son contundentes. Los autores señalan que aún no es posible afirmar que se dispone de tratamientos que combata la COVID-19 efectivamente.

show abstract

“…Es un agente zoonótico emergente que apareció en diciembre de 2019 y causa la enfermedad del coronavirus 2019 (COVID-19), este presenta un cuadro que fluctúa desde episodios leves pseudogripales a otros graves e incluso potencialmente mortales debido, sobre todo, a insuficiencia respiratoria aguda y en algunos casos a una condición respiratoria de cuidados críticos, que requiere un manejo especializado en las unidades de cuidados intensivos 1,2 .…”

Section: Introductionunclassified

Infección bacteriana asociada a ventilación mecánica en pacientes de UCI-COVID-19 del Hospital Homero Castanier Crespo

Yumbla¹

2022

INSPILIP

View full text Add to dashboard Cite

Introduction: bacterial infections associated with health care, in the intensive care unit (ICU), represent a significant problem at the global and local levels, in the context of the health crisis caused by COVID-19. In fact, a significant number of hospitalized patients develop dangerous secondary bacterial infections. Objective: To determine the incidence of bacterial infection associated with mechanical ventilation, in patients with COVID-19, in the ICU of the Homero Castanier Crespo Hospital. Methodology: A retrospective, descriptive study with a quantitative approach was carried out. In the period May 2020 - April 2021, the results of microbiological cultures of 70 samples of endotracheal secretion were analyzed. The study population was characterized by descriptive statistics. Results: In 71,4 % of cultures, positivity for bacteria was reported. Regarding the study population, men represented 80 %, (n=40), the average age was 56 years. 66 %, (n=33) of patients came from the province of Cañar. 40 % of the studied sample did not present a history of any morbidity, arterial hypertension represented 22 % and diabetes mellitus with 20 %, they were the main associated comorbidities. The microorganism with the highest incidence was Klebsiella pneumoniae, producer of beta lactamases and resistant to carbapenems with 90 %. Conclusion: Bacterial infections associated with mechanical ventilation had a high incidence, predominantly in males, constituting a risk factor for a poor prognosis in patients with COVID-19 as they are multi-resistant strains, especially beta-lactamase-producing Klebsiella pneumoniae.

show abstract

Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH)

Cited by 24 publications

References 98 publications

COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome

COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome

Tratamiento farmacológico en pacientes con COVID-19: una revisión integradora

Infección bacteriana asociada a ventilación mecánica en pacientes de UCI-COVID-19 del Hospital Homero Castanier Crespo

Contact Info

Product

Resources

About